- Home
- EPSM vs DMAC Comparison
EPSM vs DMAC Comparison
Compare EPSM & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSM
- DMAC
- Stock Information
- Founded
- EPSM 2010
- DMAC 2000
- Country
- EPSM China
- DMAC United States
- Employees
- EPSM N/A
- DMAC N/A
- Industry
- EPSM
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- EPSM
- DMAC Health Care
- Exchange
- EPSM Nasdaq
- DMAC Nasdaq
- Market Cap
- EPSM 185.6M
- DMAC 178.0M
- IPO Year
- EPSM 2025
- DMAC N/A
- Fundamental
- Price
- EPSM $17.50
- DMAC $3.57
- Analyst Decision
- EPSM
- DMAC Strong Buy
- Analyst Count
- EPSM 0
- DMAC 2
- Target Price
- EPSM N/A
- DMAC $8.00
- AVG Volume (30 Days)
- EPSM 155.4K
- DMAC 298.5K
- Earning Date
- EPSM 01-01-0001
- DMAC 08-06-2025
- Dividend Yield
- EPSM N/A
- DMAC N/A
- EPS Growth
- EPSM N/A
- DMAC N/A
- EPS
- EPSM 0.02
- DMAC N/A
- Revenue
- EPSM $12,518,070.00
- DMAC N/A
- Revenue This Year
- EPSM N/A
- DMAC N/A
- Revenue Next Year
- EPSM N/A
- DMAC N/A
- P/E Ratio
- EPSM $646.83
- DMAC N/A
- Revenue Growth
- EPSM N/A
- DMAC N/A
- 52 Week Low
- EPSM $4.23
- DMAC $2.65
- 52 Week High
- EPSM $29.76
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- EPSM N/A
- DMAC 48.75
- Support Level
- EPSM N/A
- DMAC $3.70
- Resistance Level
- EPSM N/A
- DMAC $3.99
- Average True Range (ATR)
- EPSM 0.00
- DMAC 0.28
- MACD
- EPSM 0.00
- DMAC 0.02
- Stochastic Oscillator
- EPSM 0.00
- DMAC 47.98
About EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.